GlassScriptPhysician profile
Sonali Mondkar
NPI 1609431519
$1,181.98
in general payments reported to CMS, 2019-2025
15 companies · $393 in 2025
The $393 reported for 2025 was more than what 75% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $161 · 2024: $628 · 2025: $393.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,182.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,181.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $479.65 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $156.06 | 2024-2025 | Breztri, Airsupra |
| Amgen INC. | $108.31 | 2024 | Repatha, Otezla |
| Glaxosmithkline, LLC. | $87.78 | 2023-2024 | Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $70.48 | 2023-2024 | Gardasil 9, Vaxneuvance, Capvaxive |
| Bayer Healthcare Pharmaceuticals INC. | $62.93 | 2025 | |
| Abbvie INC. | $42.81 | 2025 | |
| Astellas Pharma US INC | $30.70 | 2024 | Veozah |
| Pfizer INC. | $25.03 | 2024 | |
| Lilly USA, LLC | $23.48 | 2024 | Mounjaro, Zepbound |
| Cmp Pharma, INC. | $23.13 | 2024 | Norliqva, Atorvaliq, Tadliq |
| Organon LLC | $21.59 | 2025 | Nexplanon |
| Xeris Pharmaceuticals, INC. | $17.72 | 2024 | Gvoke Hypopen |
| Novartis Pharmaceuticals Corporation | $17.48 | 2024 | |
| Currax Pharmaceuticals LLC | $14.83 | 2024 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sonali Mondkar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.